Cipla all set to launch Favipiravir drug for treatment of COVID patients: CSIR

An off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for treatment of COVID-19 patients, especially in mild and moderate cases.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news